Thrombosis and Hemostasis Biomarkers Market By Biomarker Type (D-dimer, Fibrinogen, Von Willebrand Factor, Thrombin-Antithrombin Complex, P-selectin, Others); By Application (DVT & PE, Stroke, Cardiovascular Disease, Oncology, Trauma & Surgery, Sepsis, Pregnancy-related Disorders); By End User (Hospitals & ERs, Diagnostic Laboratories, Academic & Research Institutes, Outpatient Clinics & POC Settings); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Thrombosis And Hemostasis Biomarkers Market is projected to grow at a CAGR of 7.6% , reaching USD 9.5 billion by 2030 , up from an estimated USD 6.1 billion in 2024 , according to Strategic Market Research.

 

This market sits at the convergence of diagnostic innovation and public health urgency. Hemostasis and thrombosis biomarkers — like D-dimer, fibrinogen, thrombin- antithrombin complexes, and P-selectin — are no longer just confirmatory tools. They're becoming central to early detection, risk stratification, and therapy monitoring across cardiovascular disease, stroke, trauma, and oncology.

 

Over the next five years, three macro trends are accelerating this shift. First, the rising global burden of thrombotic disorders — deep vein thrombosis (DVT), pulmonary embolism (PE), and ischemic stroke — is reshaping clinical priorities. These conditions now account for nearly one in four deaths worldwide, according to WHO estimates. Second, aging populations are skewing risk profiles. As elderly cohorts expand in high-income regions and hypertension, obesity, and cancer rates climb in low- and middle-income countries, thrombosis screening is becoming a baseline requirement in hospital protocols.

 

Third, and perhaps most transformative, is the pivot toward precision diagnostics. Hospitals, labs, and even primary care clinics are integrating multiplex biomarker panels to identify thrombotic risk earlier and more accurately. This includes AI-driven analysis of coagulation signatures and the use of companion biomarkers to tailor anticoagulation therapy.

 

The stakeholder map here is diverse. IVD manufacturers are developing high-sensitivity assays for faster clot detection. Hospitals and trauma centers are embedding biomarker testing in emergency room workflows. Biopharma companies are using hemostasis biomarkers to monitor efficacy in anticoagulant drug trials. Health insurers and government payers are beginning to reimburse for preventative screening, especially in high-risk groups like post-surgical patients and oncology cohorts.

 

What’s also fueling market momentum is the growing role of these biomarkers outside of cardiology — in oncology (for paraneoplastic thrombosis), in sepsis management (D-dimer), and in obstetrics (e.g., antiphospholipid syndrome screening during pregnancy). In short, clinical utility is expanding faster than infrastructure can adapt in many regions.

 

To be honest, this used to be a niche segment tucked into general lab diagnostics. But not anymore. The pandemic’s spotlight on coagulopathy risks, combined with a decade of diagnostic innovation, has put thrombosis and hemostasis biomarkers at the frontlines of predictive and preventive medicine.

 

Market Segmentation And Forecast Scope

The thrombosis and hemostasis biomarkers market is segmented across four core dimensions — each reflecting how healthcare systems are adapting to rising demand for faster, more accurate coagulation diagnostics. While the science behind these biomarkers is complex, the market segmentation follows clinical pathways and infrastructure realities.

By Biomarker Type

This is the most granular and technically driven segmentation. Key biomarkers include:

• D-dimer Most widely adopted, especially in DVT and PE screening. Elevated D-dimer is often the first flag in ER settings for thrombotic risk.

• Fibrinogen Essential in both bleeding and clotting evaluations. Increasingly used in cardiac surgery and obstetrics.

• Von Willebrand Factor ( vWF ) A key marker in inherited bleeding disorders and endothelial dysfunction.

• Thrombin- Antithrombin Complex (TAT ) Growing use in ICU settings to monitor coagulation activation.

• P-selectin and CD40 Ligand Emerging as predictive tools in oncology and stroke diagnostics.

In 2024 , D-dimer holds the largest market share (approx. 38% ) — not surprising given its use across ERs, ICUs, and oncology support settings. However, multiplex panels combining fibrinogen, vWF , and inflammatory markers are gaining traction, particularly in academic hospitals and research centers.

 

By Application

Thrombosis and hemostasis biomarkers are deployed across a wide clinical spectrum:

• Deep Vein Thrombosis (DVT) & Pulmonary Embolism (PE)

• Stroke and Cardiovascular Disease

• Cancer-Associated Thrombosis

• Trauma and Surgery Monitoring

• Sepsis and Critical Care

• Pregnancy-related Coagulation Complications

Among these, cardiovascular and cerebrovascular applications dominate, accounting for a significant portion of testing volume globally. But oncology is the fastest-growing segment — fueled by rising cancer incidence and the risk of thromboembolic events in chemotherapy patients.

Use case expansion is also happening in unlikely areas — such as pre-operative risk assessment and personalized anticoagulation therapy titration.

 

By End User

• Hospitals & Emergency Departments Core testing hubs. Most high-throughput coagulation assays are run here, particularly in stroke-ready or trauma-certified centers.

• Diagnostic Laboratories Handle both routine and specialized biomarker panels — especially for outpatient referrals or long-term care patients.

• Academic & Research Institutions Heavy users of newer and experimental biomarkers. They also contribute significantly to assay validation studies.

• Point-of-Care (POC) Clinics A nascent segment, but growing. Rapid D-dimer kits are now being used in urgent care settings and mobile clinics.

In 2024 , hospitals remain the largest end users by revenue, but diagnostic labs are closing the gap — especially in Europe and Asia, where test volumes are growing through government-funded screening programs.

 

By Region

Standard geographic segmentation applies:

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East & Africa

We'll explore this in detail in Section 5, but for now, it's worth noting: Asia Pacific is the fastest-growing region , driven by large population bases, rising cardiovascular risk factors, and expanding lab infrastructure in India and China.

 

Scope Note:

While the segmentation appears diagnostic-heavy, it’s also shifting toward therapy-linked analytics. Vendors are bundling biomarker kits with anticoagulant management tools or clinical decision support software. In essence, these aren't just lab tests — they’re evolving into clinical solutions.

 

Market Trends And Innovation Landscape

The thrombosis and hemostasis biomarkers market is undergoing a quiet revolution. What used to be a routine, reactive test set is now central to predictive care, personalized medicine, and therapeutic monitoring. This shift is being driven by rapid innovation across diagnostics, informatics, and even drug development. Here’s how the landscape is evolving:

Multiplexing is Becoming the Norm

Single-marker testing — like standalone D-dimer — still dominates in emergency settings. But in outpatient and chronic care management , multi- analyte panels are gaining traction. Labs and vendors are combining D-dimer, CRP, fibrinogen, and IL-6 to provide a more holistic picture of thromboinflammatory states. These panels are especially useful in oncology, where clotting risk is dynamic and tied to tumor progression.

One leading diagnostic lab in Germany recently reported that multiplex biomarker panels reduced unnecessary imaging referrals by 27% in suspected DVT cases.

 

AI and Algorithmic Risk Scoring Are Taking Off

Hospitals are now embedding AI-powered risk stratification tools that interpret biomarker levels alongside patient history and vitals. These systems help flag silent thrombotic risk, particularly in ICU and post-operative patients. The most advanced platforms can:

• Auto-prioritize test results

• Suggest imaging or anticoagulation pathways

• Trigger alerts based on dynamic biomarker trends

Startups and diagnostic majors alike are racing to integrate these tools into LIS and EMR platforms. The end goal? Triage patients before a clot forms.

 

Liquid Biopsy Meets Coagulation Science

In oncology and neurology, there’s growing overlap between liquid biopsy platforms and coagulation diagnostics. A few players are exploring cfDNA , microvesicles , and tumor-associated coagulation markers to identify thrombotic complications earlier. This cross-pollination may redefine how hemostasis is monitored in cancer patients — particularly those on immunotherapy, where clotting risk is unpredictable.

 

POC Devices Are Shrinking Testing Barriers

Point-of-care D-dimer testing isn’t new. What’s changed is the accuracy, portability, and integration of these devices. Some newer handheld units now deliver quantitative results within 8–10 minutes and sync directly to hospital EMRs or cloud labs. These are finding uptake in:

• Stroke centers for rapid triage

• Rural health posts in emerging markets

• Mobile clinics supporting post-surgical follow-ups

Vendors are also developing wearable biosensor platforms t hat passively monitor clotting risk in high-risk cardiac patients — a signal that real-time hemostasis tracking may not be far off.

 

Regulatory Acceleration for Novel Biomarkers

Historically, regulatory clearance for new biomarkers was a multi-year slog. But that’s changing. Fast-track pathways for biomarkers related to stroke, COVID-induced coagulopathy, and cancer-associated thrombosis have shortened review cycles. Several biomarkers — including P-selectin and TAT complexes — are moving faster through validation thanks to this new urgency around thrombotic complications.

One expert from a U.S.-based diagnostic accelerator commented, “If a biomarker helps stratify clotting risk in real time, it’s no longer just a lab tool — it’s a clinical safety asset.”

 

Partnerships Are Driving Cross-Disciplinary Innovation

We're also seeing a surge in collaborations between biopharma, diagnostics, and AI startups . Some notable examples include:

• Pharma companies using hemostasis biomarkers as companion diagnostics in anticoagulant trials

• University labs working with IVD firms to validate sex-specific coagulation profiles

• AI vendors training predictive models on millions of anonymized biomarker test results

The result is a feedback loop where diagnostics influence therapy design — and vice versa.

Bottom line: Innovation here isn’t about inventing new tests from scratch. It’s about re-engineering when, how, and why these biomarkers are used — shifting them from passive indicators to real-time clinical decision tools.

 

Competitive Intelligence And Benchmarking

While the thrombosis and hemostasis biomarkers market has historically been led by a few diagnostic majors, the competitive dynamic is now broader and more layered. The current race is no longer about who offers the most biomarkers — it's about who can deliver faster, more actionable, and integrated results across a spectrum of clinical use cases.

Roche Diagnostics

Still a dominant force, Roche leads in both reagent kits and coagulation analyzers. Their Elecsys D-dimer assay remains a trusted tool in hospital labs. But more recently, the company has shifted toward algorithm-driven platforms — integrating biomarker readings into broader cardiovascular risk dashboards.

Roche also leverages its strong hospital network and LIS integration to offer bundled diagnostics, giving it an edge in large tenders and government partnerships.

 

Siemens Healthineers

Siemens’ strength lies in its central lab systems and modular coagulation analyzers like Atellica . They're targeting labs looking to scale with standardized workflows , especially in Europe and Asia. The company has also made strategic moves into point-of-care testing , offering portable kits with cloud-sync capabilities.

It’s not just about machines for Siemens — it’s about embedding clinical decision support tools around each test. This approach has made them a preferred partner in several stroke network programs.

 

bioMérieux

bioMérieux is pushing aggressively into sepsis and thrombo -inflammation diagnostics . Their strength lies in multi-marker panels for ICU and emergency settings. With recent acquisitions focused on rapid immunoassays and microbiology AI platforms, they're positioning themselves at the intersection of infection and coagulation — a space that expanded dramatically during the COVID-19 pandemic.

They’re also involved in R&D collaborations around next-gen biomarkers linked to endothelial damage and platelet activation.

 

Werfen (Instrumentation Laboratory)

A specialized player, Werfen focuses on hemostasis, acute care, and critical bleeding management . Their ACL TOP systems and HemosIL assay range are widely used in trauma and transplant centers. Werfen’s edge is precision: they emphasize real-time, high-throughput performance — not just biomarker breadth.

They’re strong in North America and Europe , particularly where hospitals need advanced coagulation support alongside surgery and oncology units.

 

Abbott Laboratories

Abbott has focused more on point-of-care coagulation testing , especially D-dimer and cardiac markers. Their i -STAT handheld analyzers are used in field hospitals, rural clinics, and by paramedics in stroke triage settings.

Their latest push includes expanding home testing for post-operative clot risk , aiming to offer INR and D-dimer combo solutions for patients on long-term anticoagulants. That said, Abbott's biomarker portfolio isn't as deep, but its accessibility and scale make it a critical player in underserved regions.

 

Up-and-Coming Entrants

Several niche and emerging companies are making waves:

• Entegrion – focused on military-grade coagulation diagnostics for trauma care.

• T2 Biosystems – exploring magnetic resonance-based biomarker detection for rapid sepsis-related clotting assessment.

• PATHFAST (Mitsubishi Chemical) – developing compact analyzers ideal for ICUs and emergency wards in Asia and Latin America.

These smaller firms are often agile, targeting specific use cases like obstetric hemorrhage or cancer-associated thrombosis, which larger players sometimes overlook.

 

Competitive Landscape Summary:

• Roche and Siemens dominate centralized platforms with broad clinical reach.

• Werfen and bioMérieux lead in specialized critical care and acute applications.

• Abbott and newcomers are expanding access through decentralized and mobile tools.

What’s becoming clear is that success in this market isn’t just about test performance — it’s about supporting workflow, risk scoring, and clinical decision-making. Trust and interoperability are often just as important as biomarker sensitivity.

 

Regional Landscape And Adoption Outlook

Adoption of thrombosis and hemostasis biomarkers isn’t uniform — it's shaped by infrastructure maturity, disease burden, and how each region approaches lab diagnostics. In some countries, biomarker testing is embedded in routine risk scoring. In others, it's still limited to high-risk hospital cases. What follows is a regional breakdown of where growth is coming from — and why.

North America

Still the largest and most mature market, North America benefits from well-funded hospitals , strong lab infrastructure , and wide clinical acceptance of biomarkers like D-dimer and fibrinogen. In the U.S., these tests are deeply integrated into ER protocols, especially for stroke, DVT, and post-surgical monitoring .

What’s accelerating here now is algorithmic care pathways . Major health systems are embedding biomarkers into EHR-triggered alerts for clotting risks. Meanwhile, outpatient settings — including telehealth providers — are beginning to rely on home-based or point-of-care kits for follow-up care in high-risk patients.

Also notable: large commercial labs are launching direct-to-consumer thrombosis panels, marketed to individuals with family history or on long-haul flights.

 

Europe

Europe mirrors North America in biomarker deployment, but with stronger public health mandates . Countries like Germany, France, and the UK offer reimbursement for pre-emptive biomarker screening in cancer patients and high-risk pregnancy cases. The EU’s updated IVDR regulations have also pushed vendors toward higher test precision and standardization.

A unique trend here is the focus on aging and frailty . Nations like Sweden and the Netherlands are integrating coagulation markers into geriatric care pathways — especially for fall risk and post-fracture thromboembolic prevention.

Eastern Europe, however, shows a split pattern . Urban hospitals in Poland or Czechia are on par with Western Europe, while rural facilities still rely heavily on general labs with limited access to newer biomarker panels.

 

Asia Pacific

This is the fastest-growing region , but also the most diverse. China and India are leading the charge, driven by:

Expanding hospital networks, Rising burden of cardiovascular and cancer-related thrombosis, & Government-led digitization of lab systems.

China’s stroke centers now routinely use multi-marker risk scoring , especially in tier-1 cities. India is scaling up diagnostic capacity in its private hospital chains, and many have begun bundling D-dimer and PT tests for all surgical admissions.

Japan and South Korea, meanwhile, are innovating in AI-guided coagulation platforms for use in oncology and neurology. But challenges remain — especially in rural access, where rapid turnaround is tough without point-of-care support.

Interestingly, Southeast Asia is seeing high uptake of rapid D-dimer tests for dengue-related complications, where clotting status needs fast triage.

 

Latin America

Latin America is in transitional mode . Countries like Brazil, Mexico, and Colombia are expanding public insurance coverage for basic thrombotic panels, especially post-COVID. Adoption is strongest in urban hospitals , where trauma and cardiac units are increasingly required to maintain real-time coagulation monitoring.

That said, supply chains and budget constraints still limit access to newer biomarkers. To bridge the gap, some hospital systems are outsourcing specialized testing to regional diagnostic labs in hubs like São Paulo and Mexico City.

 

Middle East and Africa (MEA)

MEA is still underpenetrated , but select countries are investing fast. In the Middle East, nations like Saudi Arabia and the UAE are building Western-style diagnostic centers that include thrombotic biomarker suites. They're typically bundled into stroke and cardiac units within newer hospitals.

In Africa, adoption is mostly NGO-driven or donor-supported , especially for maternal health and HIV-related coagulation disorders. However, growing private hospital networks in Nigeria, Kenya, and South Africa are piloting basic point-of-care coagulation panels , especially for post-surgical care.

 

Regional Highlights:

• North America leads in integration — biomarkers linked directly to digital workflows.

• Europe leads in standardization and public screening mandates.

• Asia Pacific leads in volume and momentum — especially in stroke and cancer.

• Latin America and MEA represent white-space opportunities , especially for portable or bundled solutions.

Bottom line: growth is less about introducing new tests — and more about closing testing gaps, particularly in outpatient and preventive care.

 

End-User Dynamics And Use Case

In the thrombosis and hemostasis biomarkers market, end users aren’t just running tests — they’re making time-critical, life-altering decisions based on them. From ER physicians trying to rule out pulmonary embolism to oncologists monitoring clotting risk in chemotherapy patients, each setting demands different capabilities, turnaround times, and clinical utility. This section breaks down how the market plays out across major user groups — and where innovation is starting to shift workflows.

Hospitals and Emergency Departments

Unsurprisingly, hospitals are still the primary users of thrombosis and hemostasis biomarkers — especially in acute care, stroke units, surgical suites, and intensive care. D-dimer, PT, and fibrinogen tests are embedded in:

• Stroke triage protocols

• Pre-operative clotting risk assessment

• Monitoring of disseminated intravascular coagulation (DIC)

• Early detection of sepsis-induced coagulopathy

Turnaround time is paramount. Many hospitals now require under-30-minute lab-to-result windows , especially in chest pain or suspected DVT cases. Larger hospitals are also integrating biomarker results into clinical decision support systems , allowing providers to rapidly assign anticoagulation or imaging steps.

In trauma settings, some centers have moved toward real-time coagulation monitoring using handheld analyzers that give D-dimer and fibrinogen values at bedside — reducing preventable delays in transfusion or surgery.

 

Diagnostic Laboratories

Centralized labs, both public and private, play a growing role — especially in routine monitoring and specialty panels . Diagnostic labs handle testing for:

• Outpatient post-surgical follow-ups

• Cancer patients on thromboprophylaxis

• Pregnancy-related thrombosis screening (e.g., antiphospholipid syndrome)

• Rare bleeding or clotting disorders

What sets labs apart is scale and specialization . While hospitals focus on speed, labs optimize cost, accuracy, and broader panels . They also serve rural or tier-2 hospitals through specimen transport networks .

A growing number of labs are now offering multiplex coagulation panels bundled with inflammatory and cardiac markers — targeting primary care clinics that want actionable results without sending patients to multiple specialists.

 

Academic & Research Institutions

These users don’t just consume tests — they create the next generation of biomarkers . Academic hospitals and translational research centers often serve as:

• Validation sites for novel hemostasis assays

• Developers of population-specific biomarker ranges

• Partners in biopharma trials needing biomarker-driven safety data

They’re also driving innovation in coagulation-informatics , using AI to spot trends across millions of patient data points. Some research groups are developing predictive models for thrombosis onset in high-risk groups — including cancer patients, ICU trauma survivors, and elderly orthopedic patients.

 

Outpatient Clinics and Point-of-Care Settings

While smaller in total market share, these settings are seeing the fastest relative growth . Clinics, urgent care centers, and even mobile health units are beginning to adopt rapid D-dimer and PT/INR tests , especially in:

• Stroke-prone rural regions

• Post-chemotherapy monitoring

• Pre-travel or high-altitude risk assessment

• Maternal health programs in developing countries

Here, the priority is simplicity and portability , not depth. Compact analyzers with low training requirements and digital readout capabilities are in high demand. Expect this segment to expand sharply in regions where hospital access remains limited.

 

Use Case: Stroke Prevention in a High-Risk Outpatient Population

A cardiology clinic in Seoul, South Korea , began offering proactive screening for thrombotic risk among patients with atrial fibrillation and early-stage heart failure. Using a multiplex panel combining D-dimer, fibrinogen, and CRP , they were able to stratify patients into three risk tiers — high, moderate, and low.

Patients in the high-risk tier were referred for imaging and adjusted anticoagulant therapy. Within six months, the clinic saw a 17% drop in thrombotic events and a 23% reduction in ER referrals related to clotting complications. The panel also helped identify outliers who had elevated risk without classical symptoms , improving long-term monitoring strategies.

This isn't just diagnostics — it's early intervention, driven by data that previously would’ve only been collected reactively, after a crisis.

Bottom line: The end-user landscape is diversifying fast. High-volume hospitals need speed and integration . Labs want precision and throughput . Clinics and mobile units need portability and affordability . The vendors that win in this space are those that can flex across all of them — without compromising on reliability.

 

Recent Developments + Opportunities & Restraints

The thrombosis and hemostasis biomarkers market has seen a surge in activity over the past 24 months — from regulatory wins and product rollouts to new research partnerships and AI integrations. While innovation is opening doors to faster, more accurate, and more widely accessible testing, adoption still faces structural and operational challenges. Below is a curated look at what's new, what's promising, and what's still holding the market back.

Recent Developments (Last 2 Years)

• Siemens Healthineers introduced a next-gen automated D-dimer assay in late 2023, offering faster turnaround and enhanced specificity for emergency stroke triage. The system now integrates directly into their Atellica platform with embedded AI prioritization.

• bioMérieux announced a strategic partnership with the University of Lyon in 2024 to co-develop a multi-marker thrombo -inflammation panel for sepsis and oncology use cases. The panel combines D-dimer, IL-6, and P-selectin for early risk identification.

• Roche Diagnostics expanded its coagulation testing suite with a cloud-enabled version of its Cobas t 711 analyzer, targeting mid-sized labs in Asia and Latin America. The update includes remote diagnostics and embedded quality control tracking.

• T2 Biosystems initiated a clinical pilot in early 2024 using magnetic resonance-based biomarker detection to identify microthrombi in septic shock patients. Early results suggest faster clot detection in ICU environments with reduced false positives.

• Abbott launched an upgraded version of i -STAT D-dimer test kit its in Q2 2024, featuring smartphone-based result uploads and improved usability in field hospitals and rural health centers.

 

Opportunities

• Growth in Preventive Diagnostics: Health systems are moving toward risk-based care — particularly in post-operative patients, cancer cohorts, and elderly populations. Biomarkers that enable early intervention are being bundled into preventive screening protocols , especially in Europe and urban Asia. Vendors offering multiplex coagulation panels with reimbursement pathways are in a strong position to capitalize.

• AI-Powered Coagulation Risk Engines: The integration of biomarkers with predictive analytics and clinical decision support is just beginning. Hospitals want tools that translate raw biomarker data into risk scores — reducing over-testing and guiding care pathways. Companies that partner with EHR vendors or hospital IT teams to deliver plug-and-play solutions will see faster traction.

• Expansion into Emerging Markets via Portable Testing: Many hospitals in Latin America, Southeast Asia, and parts of Africa are now investing in low-cost, easy-to-use coagulation analyzers — either handheld or benchtop. Vendors that design for rugged, low-resource environments (with limited lab personnel or cold chains) are poised to dominate these underpenetrated regions.

 

Restraints

• Limited Reimbursement for New Biomarkers: While D-dimer and PT tests are widely reimbursed, novel biomarkers like P-selectin, TAT complexes, or CD40L often lack formal coding or payer recognition. This slows clinical adoption, even when evidence shows value — particularly in the U.S. and parts of Asia.

• Operational Fragmentation in Testing Workflows: Many hospitals and clinics still lack standardized testing pathways , resulting in delayed diagnosis or redundant testing. Without better LIS integration and care team coordination, biomarker data often gets siloed — reducing its impact on outcomes.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 6.1 Billion
Revenue Forecast in 2030	USD 9.5 Billion
Overall Growth Rate	CAGR of 7.6% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Biomarker Type, By Application, By End User, By Region
By Biomarker Type	D-dimer, Fibrinogen, vWF, TAT Complex, P-selectin, Others
By Application	DVT & PE, Stroke, Cardiovascular Disease, Oncology, Trauma/Surgery, Sepsis, Pregnancy-related Disorders
By End User	Hospitals & ERs, Diagnostic Laboratories, Academic & Research Institutes, Outpatient Clinics & POC Settings
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, Germany, U.K., France, China, India, Japan, Brazil, Mexico, UAE, South Africa
Market Drivers	- Rising global incidence of thrombotic events - Growing demand for predictive, preventive diagnostics - Innovation in AI-powered coagulation analysis
Customization Option	Available upon request